Pharmacokinetics and safety of intravitreally delivered etanercept
- PMID: 15029504
- DOI: 10.1007/s00417-004-0895-x
Pharmacokinetics and safety of intravitreally delivered etanercept
Abstract
Background: The anti-inflammatory drug etanercept may be an effective therapeutic agent in diabetic retinopathy. In order to further evaluate its potential, the pharmacokinetics and safety of this drug after intravitreal delivery were investigated.
Methods: After intravitreal administration of etanercept in rabbits, clinical examination, electroretinography (ERG), visually evoked potentials (VEP) and histology were evaluated. The pharmacokinetics and distribution of etanercept were analyzed using fluorescence-coupled protein at 0, 2, 4, and 8 weeks after injection in vitreous, retina, and choroid.
Results: No adverse effects and signs of toxicity were found. Etanercept showed peak concentrations after 4 weeks in the retina and choroid.
Conclusions: Intravitreally delivered etanercept is safe and results in high concentrations in the retina and choroid over a long period of time.
Similar articles
-
Intravitreal toxicity of high-dose etanercept.J Ocul Pharmacol Ther. 2007 Feb;23(1):57-62. doi: 10.1089/jop.2006.0083. J Ocul Pharmacol Ther. 2007. PMID: 17341152
-
Effect of intravitreal injection of norfloxacin on the retina in pigmented rabbits.Lens Eye Toxic Res. 1992;9(3-4):493-503. Lens Eye Toxic Res. 1992. PMID: 1301799
-
Injection site and pharmacokinetics after intravitreal injection of immunoglobulin G.J Ocul Pharmacol Ther. 2011 Feb;27(1):35-41. doi: 10.1089/jop.2010.0112. Epub 2010 Dec 23. J Ocul Pharmacol Ther. 2011. PMID: 21182428
-
Intravitreal acetylsalicylic acid in silicone oil: pharmacokinetics and evaluation of its safety by ERG and histology.Graefes Arch Clin Exp Ophthalmol. 2001 Mar;239(3):208-16. doi: 10.1007/s004170100255. Graefes Arch Clin Exp Ophthalmol. 2001. PMID: 11405070
-
Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling.Adv Drug Deliv Rev. 2006 Nov 15;58(11):1164-81. doi: 10.1016/j.addr.2006.07.025. Epub 2006 Sep 16. Adv Drug Deliv Rev. 2006. PMID: 17069929 Review.
Cited by
-
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs.J Vis Exp. 2016 Jul 23;(113):53878. doi: 10.3791/53878. J Vis Exp. 2016. PMID: 27500363 Free PMC article.
-
A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology.Ther Adv Ophthalmol. 2022 May 18;14:25158414221097418. doi: 10.1177/25158414221097418. eCollection 2022 Jan-Dec. Ther Adv Ophthalmol. 2022. PMID: 35602659 Free PMC article. Review.
-
Choroidal vascularity index as a biomarker of systemic inflammation in childhood Polyarteritis Nodosa and adenosine deaminase-2 deficiency.Pediatr Rheumatol Online J. 2020 Apr 3;18(1):29. doi: 10.1186/s12969-020-0417-3. Pediatr Rheumatol Online J. 2020. PMID: 32245490 Free PMC article.
-
Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR).Pharm Res. 2009 May;26(5):1236-60. doi: 10.1007/s11095-008-9728-7. Epub 2008 Oct 8. Pharm Res. 2009. PMID: 18841448
-
Evaluation of potential retinal toxicity of adalimumab (Humira).Graefes Arch Clin Exp Ophthalmol. 2009 Aug;247(8):1119-25. doi: 10.1007/s00417-009-1065-y. Epub 2009 Mar 19. Graefes Arch Clin Exp Ophthalmol. 2009. PMID: 19296122
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources